Acorda Therapeutics, Inc. Reports Unaudited Sales Results for the Fourth Quarter and Full Year of 2015; Provides Earnings Guidance for the Full Year of 2016
For the full-year, net sales were $436 million, an increase of approximately 19% from 2014.
The company provided 2016 guidance for AMPYRA net revenue of $475 million - $485 million, research and development (R&D) expense of $165 million -$175 million, and sales, general and administrative (SG&A) expense of $195 million -$205 million.